US OptionsDetailed Quotes
CELU250516C2500
- 0.05
- 0.000.00%
15min DelayClose May 1 15:55 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume316 Open Interest2.50Strike Price0.00Turnover204.74%IV62.42%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1738Delta0.4030Gamma31.42Leverage Ratio-0.0057Theta0.0001Rho5.46Eff Leverage0.0008Vega
Celularity Stock Discussion
Sign in to post a comment
$Celularity (CELU.US)$ Bounced off support. Could be a triple witching stock and would reach 3.55.
$Citius Oncology (CTOR.US)$ Bounced right before its lowest low.
$Freight Technologies (FRGT.US)$ Started uptrend with borrow rate increasing 300%.
$Venus Concept (VERO.US)$ volume will run this way up.
$Citius Oncology (CTOR.US)$ Bounced right before its lowest low.
$Freight Technologies (FRGT.US)$ Started uptrend with borrow rate increasing 300%.
$Venus Concept (VERO.US)$ volume will run this way up.
5
1
$Celularity (CELU.US)$
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Tuesday, 25th February at 8:00 am
FLORHAM PARK, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that on December 19, 2024, it received recommendation letters from the US Food and Drug Administration, or FDA, Tissue Reference Group, o...
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Tuesday, 25th February at 8:00 am
FLORHAM PARK, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that on December 19, 2024, it received recommendation letters from the US Food and Drug Administration, or FDA, Tissue Reference Group, o...
2
$Celularity (CELU.US)$ Reuters
1 min ago
Celularity Receives FDA Tissue Reference Group Recommendation Letters for Its Natalin and Acelagraft™ Wound Care Products
1 min ago
Celularity Receives FDA Tissue Reference Group Recommendation Letters for Its Natalin and Acelagraft™ Wound Care Products
1
$Celularity (CELU.US)$
Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential?
Can This New Cell Therapy Manufacturing Deal Transform Celularity's Revenue Potential?
$Celularity (CELU.US)$ Reuters· just
Celularity Enters Strategic Collaboration Agreement With Clinical Stage Cell Therapy Company
Celularity Enters Strategic Collaboration Agreement With Clinical Stage Cell Therapy Company
1
$Celularity (CELU.US)$
I took a position here earlier solely based on the chart and today’s activity. It's giving that run vibe 🏃♀️
I took a position here earlier solely based on the chart and today’s activity. It's giving that run vibe 🏃♀️
1
$Celularity (CELU.US)$
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
Tuesday, 10th December at 8:00 am
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq"), confirming that Celularity has regained compliance with Nasdaq Listing ...
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
Tuesday, 10th December at 8:00 am
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq"), confirming that Celularity has regained compliance with Nasdaq Listing ...
2
$MSP Recovery (LIFW.US)$ Ticker change to MSPR Monday to consolidate services. Even with negative profit margin, of note, company had $10M settlements from property and casualty insurers and acquired Medicare claims valued $10.6B. Low float. Currently trading above 10/20 EMA suggesting short term bullishness. SI 162%, 0 shares LTB
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
51
25
6
No comment yet
萬軍無兵策天鳳 : The company is going to issue more Stocks, everyone should not be fooled lol.